Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

3.149.213.179
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Homozygous Familial Hypercholesterolemia (HoFH)

Interim analysis shows lomitapide safe and effective in Japanese patients with HoFH

Posted on
Listen to this article
2 min

Despite the occurrence of drug-related adverse events, including liver-related issues and gastrointestinal disorders, lomitapide demonstrated effectiveness in reducing LDL-C levels in Japanese patients with homozygous familial hypercholesterolemia.

The study suggests that lomitapide is safe and effective in real-world clinical practice in Japan, highlighting its potential as a treatment option for this patient population.

-Advertisement-
-Advertisement-

The study, which included 39 patients, examined the use of lomitapide over a period of 42 months. The median daily dose of lomitapide administered was 9.8 mg.

Results found that 74 drug-related adverse events were reported in 61.5% of patients. These adverse events included liver-related issues in 35.9% of patients, gastrointestinal disorders in 48.7%, and 1 case of a bleeding disorder. In response to these events, the dose of lomitapide was reduced for 39.2% of cases, temporarily withdrawn for 12.2%, and discontinued in only 1 instance.

Despite these adverse events, the study found that lomitapide demonstrated effectiveness in reducing LDL-C levels. The mean LDL-C level decreased from 225.9 mg/dl (5.8 mmol/l) before treatment to 159.4 mg/dl (4.1 mmol/l) after 12 months of treatment (P = 0.0245).

Reference
Harada-Shiba M, Haruna S, Kogawa N. Real-world safety and efficacy of lomitapide in homozygous familial hypercholesterolemia: interim report of special-use survey in Japan. Future Cardiol. 2024;doi: 10.2217/fca-2023-0136. Epub ahead of print. PMID: 38420884.

-Advertisement-
-Advertisement-
-Advertisement-